Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli



Status:Recruiting
Conditions:Pneumonia
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 95
Updated:11/8/2018
Start Date:October 2012
End Date:September 2021
Contact:Jolene Daniel, CCRP
Email:jolened@med.umich.edu
Phone:734-615-1901

Use our guide to learn which trials are right for you!

Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli

Approximately 444 subjects who are greater than or equal to 18 to 95 years of age, are
non-pregnant, and are in the inpatient setting of one of the study sites will be evaluated to
treatment efficacy. Analysis will include subjects with bloodstream infection (BSI) or
pneumonia due to at least one of the following gram-negative bacilli organisms: Acinetobacter
baumannii, Klebsiella spp, Escherichia coli, Enterbactor spp. and/or Pseudomonas aeruginosa
that demonstrates in vitro non-susceptibility defined as extensively drug-resistant
Gram-negative bacilli (XDR-GNB) which includes XDR-AB, XDR-PA and CRE. If a subject has both
BSI and pneumonia at the time of study enrollment, they will be included as a subject with
pneumonia.

Objectives:

Primary:

•Determine whether the treatment regimen of Colistimethate sodium (colistin) combined with a
carbapenem (imipenem or meropenem) is associated with a decreased risk for mortality compared
to colistin alone for subjects with bloodstream infection (BSI) and/or pneumonia due to
XDR-GNB.

Secondary:

•Determine what treatment regimen (colistin monotherapy or colistin combined with a
carbapenem (imipenem or meropenem) is more likely to reduce the emergence of colistin
resistance among XDR-GNB isolates during therapy.

The Gram-negative bacilli organisms Acinetobacter baumannii, Klebsiella spp., Escherichia
coli, Enterbactor spp. and Pseudomonas aeruginosa have become a frequent cause of bloodstream
infection and pneumonia in the hospital and other healthcare settings. Among these pathogens,
antimicrobial resistance has emerged to many classes of antimicrobial agents. Most
concerning, has been the emergence of resistance to group 2 carbapenems (such as imipenem).
In several regions of the world, including Southeastern Michigan, strains of extensively-drug
resistant Gram-negative bacilli (XDR-GNB) that exhibit resistance to most, and in some cases
all types of available antimicrobial agents, including group 2 carbapenems, have emerged and
disseminated. Treatment options for XDR-GNB typically include Colistimethate sodium (referred
to as colistin in this study), used alone (monotherapy) or in combination with other agents.
Unfortunately, resistance to colistin has begun to emerge in some strains of XDR-GNB, which
is a truly concerning development, since colistin is one of the last remaining treatment
options for XDR-GNB. No prospective, randomized controlled trials have been conducted to
evaluate the clinical efficacy of colistin monotherapy versus colistin-containing combination
therapy or the impact of these therapeutic modalities on the emergence of colistin resistance
among XDR-GNB. We plan to conduct a double-blind randomized controlled trial including
patients with pneumonia and bloodstream infection due to XDR-GNB. After enrollment, subjects
will be randomized to receive 14 days of either colistin monotherapy or colistin plus
meropenem.

In the Detroit metro area, infections due to XDR-GNB have developed into a regional challenge
and common problem. We have assembled a multi-disciplinary team that includes Infectious
Diseases researchers, clinicians, infectious diseases pharmacists, microbiologists,
epidemiologists and statistical experts to address critically important questions and
challenges regarding the management of bloodstream infection and pneumonia due to XDR-GNB.
Specifically, we hypothesize that the combination of colistin and imipenem will provide
superior efficacy in the treatment of XDR-GNB pneumonia and bloodstream infection and will
prevent the emergence of decreased susceptibility to colistin among XDR-GNB strains. We also
aim to analyze tools that could be used in "real time" to aid clinicians treating patients
with infection due to XDR-GNB. For example, we aim to analyze the association between the
presence of in vitro synergy of the colistin and carbapenem (imipenem or meropenem)
combination (as determined by E-test) and clinical outcomes; and the association between
colistin plasma levels and clinical outcomes and the development of nephrotoxicity.

Inclusion Criteria:

- Hospitalized Adults (> 18 years to 95 years of age), at one of the study sites.

- Diagnosis of BSI and/or pneumonia due to a preliminary result of gram-negative
non-lactose fermenter that is oxidase negative; or a final results of XDR-A.
baumannii; carbapenem-resistant Enterobacteriaciae; or XDR- P. aeruginosa and/or
patients with suspected BSI and/or HAP and who have had a prior history (within last 6
months) of XDR-GNB that was susceptible to colistin.

o If final results do not indicate that the pathogen is an XDR-GNB, and identifies
alternative treatment options, the patient would be eligible for the study if the
subject is allergic to all the alternative treatment options.

- Patients with polymicrobial respiratory or blood infections, including XDR-GNB and one
or more pathogens, will be included in the study, as long as the XDR-GNB is determined
to be a true pathogen (AB, CRE or PA). Other pathogens will be treated with
antimicrobial agents as determined by the treating physician.

- If more than one XDR-GNB study pathogens is identified as a study pathogen causing BSI
and/or pneumonia, then the first study pathogen recovered will be considered as the
primary study pathogen. If more than one study pathogen is recovered from the same
culture, then the infection will be categorized as being caused by multiple study
pathogens.

- Patients with a life expectancy of > 24 hours

- Signed written informed consent and HIPAA Authorization form (US sites)

Exclusion Criteria:

- Female patients who are pregnant

- Female patients who are nursing

- Patients who are prisoners

- Patients who are less than 18 years of age or greater than or equal to 96 years of age

- Patients with neutropenia (WBC < 500 cells/mm3)

- The presence of any of the following known clinical syndromes involving XDR-GNB as a
pathogen which necessitate durations of antimicrobial therapies greater than 14 days:
endocarditis, osteomyelitis, prosthetic joint infections, meningitis and/or other
central nervous system infections.

- Patients receiving valproic acid (with or without a known seizure disorder).

- Patients who received 72 hours or more of polymyxin treatment (intravenous or inhaled
[pneumonia]) within 96 hours of enrollment.

- Patients who have end-stage renal disease requiring hemodialysis, will be excluded
from evaluation pertaining to nephrotoxicity in the per protocol population.

- Patients with known Type 1 or other severe drug allergy to either of the study drugs
or to β-lactams.
We found this trial at
8
sites
5050 Anthony Wayne Dr
Detroit, Michigan 48201
(313) 577-2424
Principal Investigator: Sorabh (Rob) Dhar, MD
Phone: 313-966-0045
Wayne State University Founded in 1868, Wayne State University is a nationally recognized metropolitan research...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
410 W 10th Ave
Columbus, Ohio 43210
(614) 293-8652
The Ohio State University, Wexner Medical Center Located in Columbus, The Ohio State University Wexner...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Daniel Kett, MD
Phone: 305-585-6820
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
Royal Oak, Michigan 48073
Principal Investigator: Matthew Sims, MD, PhD
Phone: 248-551-0027
?
mi
from
Royal Oak, MI
Click here to add this to my saved trials
?
mi
from
Sofia,
Click here to add this to my saved trials